Client of a consultant lobbyist
Vertex Pharmaceuticals (Canada) Inc.
- Meetings this Parliament
- 6
- With MPs
- 2
- Since Nov 2021
- 7
- Active registrations
- 1
Most recent reported meeting: Mar 24, 2026.
Lobbying by Vertex Pharmaceuticals (Canada) Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Aug 14, 2026
Consultant Johanne Chambers of 3Sixty Public Affairs Inc.
Consultant lobbyists
-
Johanne Chambers
Former public office holder
Formerly Negotiator, Negotiations East Branch, Indian and Northern Affairs Canada (2007–2014)
Formerly Lawyer, Department of Legal Services for INAC, Department of Justice (2006–2007)
Formerly Senior Policy Analyst, Treaties, Research, International and Gender Equality Branch, Indian and Northern Affairs Canada (2004–2006)
Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (8)Hide details
- Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
- Implementation of Canada's action plan for pain and federal initiatives related to pain management.
- Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
- Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
- Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
- Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
- Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
- Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Registration 942584-375135-7. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Johanne Chambers · Consultant
- Dan Mazier · Member of Parliament
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions. Read more
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Implementation of Canada's action plan for pain and federal initiatives related to pain management.
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
-
Reported by Johanne Chambers · Consultant
- Michael Coteau · MP
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Read more
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
-
Reported by Johanne Chambers · Consultant
- Suze Youance · Senator, Senate of Canada
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals. Read more
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
-
Reported by Johanne Chambers · Consultant
- Marie-Françoise Mégie · Senator, Senate of Canada
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Read more
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
-
Reported by Johanne Chambers · Consultant
- Sharon Burey · Senator, Senate of Canada
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Read more
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
-
Reported by Johanne Chambers · Consultant
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Read more
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
-
Reported by Johanne Chambers · Consultant
- Marie-Françoise Mégie · Senator, Senate of Canada
- Nicolas Thibodeau · Parliamentary Affairs Advisor, Senate of Canada
BudgetHealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.